市場調查報告書
商品編碼
949423

全球膀胱過度活躍症(OAB)治療市場(2019-2025)

Global Overactive Bladder Treatment Market 2019-2025

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

據估計,在預測期內,全球膀胱過度活動症治療市場將顯示溫和增長。人口老齡化是市場增長的主要驅動力。根據聯合國的數據,2019年全球有70,300萬人為65歲及以上。到2050年,老年人口預計將翻一番,達到15億。 65歲以上的人口比例從1990年的6%增加到2019年的9%。隨著年齡的增長,出現帕金森氏病和尿失禁等症狀的風險增加。尿失禁在老年人中很常見,尤其是在女性中。

膀胱和尿道會隨著年齡而發生結構性變化,這可能導致尿失禁的發展。這導致對膀胱過度活躍的治療的需求,其中膀胱不能正常容納尿液。抗膽鹼能藥物可用於控制膀胱過度活動和尿失禁的症狀。這些藥物減少了滲漏的可能性,可以與行為療法相結合以減輕膀胱過度活動症的症狀。

在地理上,市場分為四個主要區域。北美,歐洲,亞太地區和其他國家(RoW)。由於對神經刺激療法的需求增加以及該地區帕金森氏病和尿失禁的患病率上升,預計北美在2018年將佔有很大的市場份額。據估計,在亞太區域,由於人口老齡化和與尿有關的疾病大量增加,在預測期內有潛在的增長。印度製藥公司,如Cipla和Glenmark Pharmaceuticals Ltd.向過度膀胱治療劑的發展轉移,有望進一步促進該地區的市場增長。

市場上的重要參與者包括Astellas Pharma Inc.,Pfizer Inc.,Medtronic plc,Allergan plc,Mylan NV等。產品發佈被市場參與者認為是增加市場份額的重要策略。例如,在2019年4月,Teva製藥工業有限公司宣佈在美國推出5 mg和10 mg VESIcare(琥珀酸索非那新)仿製藥片。這些是毒蕈鹼拮抗劑,已顯示可治療膀胱過度活動症,並具有急迫性尿失禁,尿急和尿頻的症狀。隨著這一新產品的發佈,該公司有望增加在美國的市場份額。

本報告調查了全球膀胱過度活動症治療市場,並概述了市場,對市場增長因素和阻塞因素的分析,市場規模趨勢以及按治療,應用和地區,競爭情況和主要因素進行的預測它提供系統信息,例如公司簡介和市場機會。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 公司份額分析
  • 主要策略分析
  • 主要公司分析
    • Astellas Pharmaceutical Co.,Ltd. 輝瑞公司
    • 美敦力公司
    • Allagan plc
    • Mylan NV

第4章市場決定因素

4.1動機

4.2抑制因素

4.3機會

第5章市場細分

  • 通過治療
    • 抗膽鹼藥
    • 膀胱內註射
    • Mirabegron
    • 神經刺激
    • 其他
  • 通過申請
    • 神經源性膀胱過度活動症
    • 特發性膀胱過度活動症

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章公司簡介

  • Alembic Pharmaceuticals Ltd.
  • Allergan plc
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Axonics Modulation Technologies, Inc.
  • BlueWind Medical
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Endo International plc
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • Laborie, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Medtronic plc
  • Mylan N.V.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2021742

Global Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Therapy (Anticholinergics, Intravesical Instillation, Mirabegron, Neurostimulation, and Others), By Application (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder) and Forecast, 2019-2025

The global overactive bladder treatment market is estimated to witness moderate growth during the forecast period. The increasing ageing population is the major factor in driving the market growth. As per the United Nations, in 2019, 703 million people were aged 65 and over globally. In 2050, the number of older persons is anticipated to double to 1.5 billion. The share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. The risk of developing conditions including Parkinson's disease and urinary incontinence increases with age. Urinary incontinence is common in the elderly population, particularly in women.

Structural changes occur with the age in the bladder and urethra that may lead to the development of urinary incontinence. This, in turn, contributes to the demand for overactive bladder treatment in which the bladder is not able to normally hold urine. Anticholinergics medications are used to control the symptoms of overactive bladder and urge incontinence. These medications can reduce the possibility of leakage and can be used in combination with behavioral therapies to ease the symptoms of overactive bladder.

Geographically, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and Rest of the world (RoW). In 2018, North America is anticipated to hold a significant share in the market owing to the increasing demand for neurostimulation therapy and the increasing prevalence of Parkinson's disease and urinary incontinence in the region. Asia-Pacific is estimated to witness potential growth during the forecast period owing to the significant rise in the ageing population and urinary-associated disorders in the region. The rising shift towards Indian pharmaceutical companies, including Cipla and Glenmark Pharmaceuticals Ltd. towards the development of medicines for overactive bladder treatment is further anticipated to drive the market growth in the region.

Some crucial players in the market include Astellas Pharma Inc., Pfizer Inc., Medtronic plc, Allergan plc, and Mylan N.V. Product launches are considered as a key strategy adopted by the market players to expand market share. For instance, in April 2019, Teva Pharmaceutical Industries Ltd. declared the introduction of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the US. These are a muscarinic antagonist indicated to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This new launch will support the company to increase its market share in the US.

Research Methodology

The market study of the global overactive bladder treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Overactive Bladder Treatment Market Research and Analysis by Therapy

2. Global Overactive Bladder Treatment Market Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global overactive bladder treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global overactive bladder treatment market.
  • Insights about market determinants, which are stimulating the global overactive bladder treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdowns
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Astellas Pharma Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Medtronic plc
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Allergan plc
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Mylan N.V.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Overactive Bladder Treatment Market by Therapy
    • 5.1.1. Anticholinergics
      • 5.1.1.1. Solifenacin
      • 5.1.1.2. Darifenacin
      • 5.1.1.3. Oxybutynin
      • 5.1.1.4. Trospium
      • 5.1.1.5. Tolterodine
      • 5.1.1.6. Fesoterodine
      • 5.1.1.7. Others
    • 5.1.2. Intravesical Instillation
    • 5.1.3. Mirabegron
    • 5.1.4. Neurostimulation
    • 5.1.5. Others
  • 5.2. Global Overactive Bladder Treatment Market by Application
    • 5.2.1. Neurogenic Overactive Bladder
      • 5.2.1.1. Parkinson's Disease
      • 5.2.1.2. Stroke
      • 5.2.1.3. Multiple Sclerosis
      • 5.2.1.4. Spinal Cord Injury
      • 5.2.1.5. Others
    • 5.2.2. Idiopathic Overactive Bladder

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alembic Pharmaceuticals Ltd.
  • 7.2. Allergan plc
  • 7.3. Apotex Inc.
  • 7.4. Astellas Pharma Inc.
  • 7.5. Axonics Modulation Technologies, Inc.
  • 7.6. BlueWind Medical
  • 7.7. Cadila Healthcare Ltd.
  • 7.8. Cipla Ltd.
  • 7.9. Endo International plc
  • 7.10. Glenmark Pharmaceuticals Ltd.
  • 7.11. Hisamitsu Pharmaceutical Co., Inc.
  • 7.12. Intas Pharmaceuticals Ltd.
  • 7.13. Johnson & Johnson Services, Inc.
  • 7.14. Laborie, Inc.
  • 7.15. Lupin Ltd.
  • 7.16. Macleods Pharmaceuticals Ltd.
  • 7.17. Medtronic plc
  • 7.18. Mylan N.V.
  • 7.19. Pfizer Inc.
  • 7.20. Sanofi S.A.
  • 7.21. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 2. GLOBAL ANTICHOLINERGICS FOR OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL INTRAVESICAL INSTILLATION FOR OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL MIRABEGRON FOR OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL NEUROSTIMULATION FOR OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL OTHER OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 8. GLOBAL NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 14. EUROPEAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 16. EUROPEAN OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 18. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 19. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 20. REST OF THE WORLD OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 21. REST OF THE WORLD OVERACTIVE BLADDER TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
  • 2. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
  • 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)